These findings highlight that METTL3 enhances M2‐driven MMT in renal fibrosis during CAR by promoting the TGF‐β1/Smad3 axis, suggesting that METTL3 is a promising therapeutic target for mitigating renal fibrosis in CAR. This evidence concerns the gene TGFB1 and renal fibrosis.